|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Telavancin hydrochloride]] |
| {{Telavancin}}
| |
| {{CMG}}; {{AE}} {{chetan}}
| |
| | |
| ==Overview==
| |
| '''Telavancin''' is a [[bactericidal]] [[lipoglycopeptide]] under trial for use in [[MRSA]] or other [[Gram-positive]] infections.
| |
| | |
| On October 19, 2007, the [[United States|US]] [[Food and Drug Administration]] issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. <ref>{{cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= }}</ref>
| |
| | |
| ==Category==
| |
| Glycopeptide
| |
| ==US Brand Names==
| |
| VIBATIV<sup>®</sup>
| |
| ==FDA Package Insert==
| |
| | |
| ''' [[Telavancin description|Description]]'''
| |
| '''| [[Telavancin clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Telavancin microbiology|Microbiology]]'''
| |
| '''| [[Telavancin indications and usage|Indications and Usage]]'''
| |
| '''| [[Telavancin contraindications|Contraindications]]'''
| |
| '''| [[Telavancin warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Telavancin adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Telavancin drug interactions|Drug Interactions]]'''
| |
| '''| [[Telavancin overdosage|Overdosage]]'''
| |
| '''| [[Telavancin clinical studies|Clinical Studies]]'''
| |
| '''| [[Telavancin dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Telavancin how supplied|How Supplied]]'''
| |
| '''| [[Telavancin labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| Like vancomycin, telavancin inhibits bacterial [[cell wall]] synthesis by binding to the <small>D</small>-[[Alanine|Ala]]-<small>D</small>-Ala terminus of the peptidoglycan in the growing cell wall (see [[Vancomycin#Pharmacology and chemistry|Pharmacology and chemistry of vancomycin]]). In addition, it disrupts bacterial [[Biological membrane|membranes]] by [[depolarization]].<ref name=HIG2005>{{Cite journal| url=http://aac.asm.org/cgi/content/full/49/3/1127| title=Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus| journal=Antimicrobial Agents and Chemotherapy| pages=1127–1134| volume=49| issue=3| year=2005| doi=10.1128/AAC.49.3.1127-1134.2005| pmid=15728913| last1=Higgins| first1=DL| last2=Chang| first2=R| last3=Debabov| first3=DV| last4=Leung| first4=J| last5=Wu| first5=T| last6=Krause| first6=KM| last7=Sandvik| first7=E| last8=Hubbard| first8=JM| last9=Kaniga| first9=K| pmc=549257}}</ref><ref>{{Cite journal
| |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |